220 related articles for article (PubMed ID: 15591508)
1. CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin.
Byrne FR; Morony S; Warmington K; Geng Z; Brown HL; Flores SA; Fiorino M; Yin SL; Hill D; Porkess V; Duryea D; Pretorius JK; Adamu S; Manoukian R; Danilenko DM; Sarosi I; Lacey DL; Kostenuik PJ; Senaldi G
Gut; 2005 Jan; 54(1):78-86. PubMed ID: 15591508
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice.
Kostenuik PJ; Bolon B; Morony S; Daris M; Geng Z; Carter C; Sheng J
Bone; 2004 Apr; 34(4):656-64. PubMed ID: 15050896
[TBL] [Abstract][Full Text] [Related]
3. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis.
Romas E; Sims NA; Hards DK; Lindsay M; Quinn JW; Ryan PF; Dunstan CR; Martin TJ; Gillespie MT
Am J Pathol; 2002 Oct; 161(4):1419-27. PubMed ID: 12368214
[TBL] [Abstract][Full Text] [Related]
5. Polyclonal expansion of adoptively transferred CD4+ alpha beta T cells in the colonic lamina propria of scid mice with colitis.
Rudolphi A; Bonhagen K; Reimann J
Eur J Immunol; 1996 May; 26(5):1156-63. PubMed ID: 8647181
[TBL] [Abstract][Full Text] [Related]
6. The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism.
Padagas J; Colloton M; Shalhoub V; Kostenuik P; Morony S; Munyakazi L; Guo M; Gianneschi D; Shatzen E; Geng Z; Tan HL; Dunstan C; Lacey D; Martin D
Calcif Tissue Int; 2006 Jan; 78(1):35-44. PubMed ID: 16362459
[TBL] [Abstract][Full Text] [Related]
7. Osteoprotegerin mitigates tail suspension-induced osteopenia.
Bateman TA; Dunstan CR; Ferguson VL; Lacey DL; Ayers RA; Simske SJ
Bone; 2000 May; 26(5):443-9. PubMed ID: 10773583
[TBL] [Abstract][Full Text] [Related]
8. Osteoprotegerin in prostate cancer bone metastasis.
Corey E; Brown LG; Kiefer JA; Quinn JE; Pitts TE; Blair JM; Vessella RL
Cancer Res; 2005 Mar; 65(5):1710-8. PubMed ID: 15753366
[TBL] [Abstract][Full Text] [Related]
9. rHuKGF ameliorates symptoms in DSS and CD4(+)CD45RB(Hi) T cell transfer mouse models of inflammatory bowel disease.
Byrne FR; Farrell CL; Aranda R; Rex KL; Scully S; Brown HL; Flores SA; Gu LH; Danilenko DM; Lacey DL; Ziegler TR; Senaldi G
Am J Physiol Gastrointest Liver Physiol; 2002 Apr; 282(4):G690-701. PubMed ID: 11897629
[TBL] [Abstract][Full Text] [Related]
10. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
Moschen AR; Kaser A; Stadlmann S; Millonig G; Kaser S; Mühllechner P; Habior A; Graziadei I; Vogel W; Tilg H
J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
[TBL] [Abstract][Full Text] [Related]
11. Colitis-inducing potency of CD4+ T cells in immunodeficient, adoptive hosts depends on their state of activation, IL-12 responsiveness, and CD45RB surface phenotype.
Claesson MH; Bregenholt S; Bonhagen K; Thoma S; Möller P; Grusby MJ; Leithäuser F; Nissen MH; Reimann J
J Immunol; 1999 Mar; 162(6):3702-10. PubMed ID: 10092833
[TBL] [Abstract][Full Text] [Related]
12. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis.
Redlich K; Görtz B; Hayer S; Zwerina J; Doerr N; Kostenuik P; Bergmeister H; Kollias G; Steiner G; Smolen JS; Schett G
Am J Pathol; 2004 Feb; 164(2):543-55. PubMed ID: 14742260
[TBL] [Abstract][Full Text] [Related]
13. RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis.
Stolina M; Adamu S; Ominsky M; Dwyer D; Asuncion F; Geng Z; Middleton S; Brown H; Pretorius J; Schett G; Bolon B; Feige U; Zack D; Kostenuik PJ
J Bone Miner Res; 2005 Oct; 20(10):1756-65. PubMed ID: 16160733
[TBL] [Abstract][Full Text] [Related]
14. Induction of wasting disease in SCID mice by the transfer of normal CD4+/CD45RBhi T cells and the regulation of this autoreactivity by CD4+/CD45RBlo T cells.
Morrissey PJ; Charrier K
Res Immunol; 1994 Jun; 145(5):357-62. PubMed ID: 7701115
[TBL] [Abstract][Full Text] [Related]
15. Immunosenescent colitogenic CD4(+) T cells convert to regulatory cells and suppress colitis.
Totsuka T; Kanai T; Nemoto Y; Tomita T; Tsuchiya K; Sakamoto N; Okamoto R; Watanabe M
Eur J Immunol; 2008 May; 38(5):1275-86. PubMed ID: 18412161
[TBL] [Abstract][Full Text] [Related]
16. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats.
Kostenuik PJ; Capparelli C; Morony S; Adamu S; Shimamoto G; Shen V; Lacey DL; Dunstan CR
Endocrinology; 2001 Oct; 142(10):4295-304. PubMed ID: 11564687
[TBL] [Abstract][Full Text] [Related]
17. Expression of pro-inflammatory cytokines by TCR alpha beta+ and TCR gamma delta+ T cells in an experimental model of colitis.
Simpson SJ; Holländer GA; Mizoguchi E; Allen D; Bhan AK; Wang B; Terhorst C
Eur J Immunol; 1997 Jan; 27(1):17-25. PubMed ID: 9021993
[TBL] [Abstract][Full Text] [Related]
18. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis.
Saidenberg-Kermanac'h N; Corrado A; Lemeiter D; deVernejoul MC; Boissier MC; Cohen-Solal ME
Bone; 2004 Nov; 35(5):1200-7. PubMed ID: 15542046
[TBL] [Abstract][Full Text] [Related]
19. Osteoclastogenesis inhibitory factor/osteoprotegerin reduced bone loss induced by mechanical unloading.
Ichinose Y; Tanaka H; Inoue M; Mochizuki S; Tsuda E; Seino Y
Calcif Tissue Int; 2004 Oct; 75(4):338-43. PubMed ID: 15549649
[TBL] [Abstract][Full Text] [Related]
20. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
Schett G; Redlich K; Hayer S; Zwerina J; Bolon B; Dunstan C; Görtz B; Schulz A; Bergmeister H; Kollias G; Steiner G; Smolen JS
Arthritis Rheum; 2003 Jul; 48(7):2042-51. PubMed ID: 12847699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
